Celularity Signs U.S. Deal with MuseCell for Dezawa Cells

Celularity's Florham Park facility is taking on its first major third-party cell therapy manufacturing program, a move that tests how purpose-built cGMP infrastructure scales to accommodate novel cellular starting materials authenticated under a proprietary method. The collaboration with MuseCell Innovations (MCI) covers U.S. production of Dezawa MuseCells (DMCs), Dezawa MuseExosomes, and Dezawa MuseSecretome, with MCI projecting aggregate purchases exceeding $300 million over five years if the relationship expands as planned.

For QA and regulatory leads, the authentication framework is the operative detail. Under the MCI platform, a preparation qualifies as a DMC product through perinatal, bone marrow, or adipose starting materials, manufactured under the licensed Dezawa Method and conformance to MCI's product specifications. Each derived product, exosomes and secretome included, carries dedicated analytical characterization, specifications, and release criteria appropriate to its distinct profile, a structure that will require Celularity's quality systems to accommodate multiple product-specific control strategies within a shared facility.

Celularity's 147,215-square-foot Florham Park site operates nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites designed for commercial-scale cellular therapy production. Integrated CMC, advanced cell manufacturing, and analytical method capabilities position the site as a CDMO-style resource, though Celularity continues to advance its own placental-derived programs in parallel. The dual-use model, proprietary pipeline alongside third-party programs, places particular emphasis on campaign segregation, contamination control, and change control documentation under 21 CFR Part 211 and applicable ICH Q10 quality system expectations.

The initial project scope is limited to establishing manufacturing capability for MCI-authenticated DMC preparations; the broader five-year projection is contingent on successful completion of that phase and subsequent agreement on additional programs. MCI describes the $300 million figure as reflecting potential future scope, not committed volume, a distinction relevant to capacity planning and resource allocation at the site level.

Measurable progress on the initial DMC manufacturing build-out at Florham Park will serve as the first indicator of whether the collaboration's projected scale is operationally achievable within the facility's current suite configuration.

Source: Celularity via Business Wire, 27 August 2026.